Résumé:
Introduction: Long COVID (LC) affects approximately 10% of individuals post SARS-CoV-2 infection, with symptoms persisting beyond 12 weeks. The
underlying mechanisms remain unclear, and current models often focus on
pre-existing comorbidities.
Methods: This cohort study aimed to identify robust biomarkers and clarify LC
pathogenesis through a comprehensive analysis performed in 32 LC individuals
26 months post-infection compared with 35 fully recovered individuals recruited
between March and July 2022. Blood and fecal samples were collected, and
multiple parameters associated with immune dysfunction, endothelial damage,
bacterial translocation, and coagulation alterations, alongside signs of viral
persistence and sociodemographic and clinical features, were analyzed.
Results: Although viral RNA was undetected on blood or stool, elevated plasma
IgG against the nucleocapsid may indicate frequent reinfections, greater
infection severity, or delayed immune normalization. Increased levels of
prothrombin, thrombin, fibrinogen, sEPCR, and CRP pointed to persistent
endothelial dysfunction and coagulation imbalance. Lower levels of the
bactericidal protein REG3A suggest potential disruptions in mucosal immune
response. We found no major differences in traditional comorbidities,highlighting that LC may stem from distinct pathogenic mechanisms beyond
pre-existing conditions. Importantly, our study revealed impaired humoral
immunity and identified an association between vaccine heterogeneity and
increased LC risk, emphasizing the relevance of consistent vaccination
strategies. A Random Forest model using the measured biomarkers achieved
100% accuracy in classifying LC individuals, reinforcing their diagnostic potential.
Discussion: These findings support a multifactorial model of LC involving
immune dysregulation and persistent endothelial damage that led to
coagulation abnormalities and a pro-thrombotic profile, supporting that LC is
more closely related to a sustained, uncontrolled inflammatory response rather
than immunodeficiency, and underscoring the value of multidimensional
biomarker profiling for guiding clinical management and prevention strategies.